title: Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.
abstract: Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft versus host disease, recurrent aphthous ulcers etc. We report a case of Stevens Johnson syndrome-toxic epidermal necrolysis developing in an elderly male who was prescribed thalidomide after being diagnosed with multiple myeloma.
authors.affiliation: Department of Dermatology, Medical College, Kolkata, West Bengal, India.
authors.forename: Anupam
authors.initials: A
authors.lastname: Das
authors.affiliation: Department of Pharmacology, Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal, India.
authors.forename: Amrita
authors.initials: A
authors.lastname: Sil
authors.affiliation: Department of Dermatology, Medical College, Kolkata, West Bengal, India.
authors.forename: Vivek
authors.initials: V
authors.lastname: Mishra
authors.affiliation: Department of Dermatology, Medical College, Kolkata, West Bengal, India.
authors.forename: Nilay Kanti
authors.initials: NK
authors.lastname: Das
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D013262:Stevens-Johnson Syndrome / Q000208:ethnology*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013792:Thalidomide
keywords: Multiple myeloma; SJS-TEN overlap; thalidomide